The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,418
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,009
Jiang, W., & Zhu, T. F. (2016) · Nature Protocols · doi:10.1038/nprot.2016.055 · Cited by 74
CRISPR-Cas9 technology: applications and human disease modelling
Torres-Ruiz, R., & Rodríguez, S. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw025 · Cited by 77
Holmgaard, A., Askou, A. L., Benckendorff, J. N. E., Thomsen, E. A., Cai, Y., Bek, T., Mikkelsen, J. G., & Corydon, T. J. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.016 · Cited by 74
Liang, Y., Iqbal, Z., Wang, J., Xu, L., Xu, X., Ouyang, K., Zhang, H., Lu, J., Duan, L., & Xia, J. (2022) · Biomaterials Science · doi:10.1039/d2bm00480a · Cited by 72
Yu, Y., Guo, Y., Tian, Q., Lan, Y., Yeh, H., Zhang, M., Tasan, I., Jain, S., & Zhao, H. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0432-1 · Cited by 76
Application of CRISPR/Cas9 in Alzheimer’s Disease
Lu, L., Xi, Y., Cai, Y., Sun, M., & Yang, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.803894 · Cited by 79
Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework
Evitt, N. H., Mascharak, S., & Altman, R. B. (2015) · The American Journal of Bioethics · doi:10.1080/15265161.2015.1104160 · Cited by 58
Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology
Zhang, D., Li, Z., & Li, J.-F. (2016) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.03.001 · Cited by 67
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 73
Genome engineering: a new approach to gene therapy for neuromuscular disorders
Nelson, C. E., Robinson-Hamm, J. N., & Gersbach, C. A. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.126 · Cited by 73
Tóth, E., Czene, B. C., Kulcsár, P. I., Krausz, S. L., Tálas, A., Nyeste, A., Varga, É., Huszár, K., Weinhardt, N., Ligeti, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky815 · Cited by 74
Jiao, X., Zhang, Y., Liu, X., Zhang, Q., Zhang, S., & Zhao, Z. K. (2019) · Biotechnology Journal · doi:10.1002/biot.201900036 · Cited by 72
Legut, M., Daniloski, Z., Xue, X., McKenzie, D., Guo, X., Wessels, H., & Sanjana, N. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.010 · Cited by 71
Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia
Conn, V. M., Gabryelska, M., Toubia, J., Kirk, K., Gantley, L., Powell, J. A., Cildir, G., Marri, S., Liu, R., Stringer, B. W., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.002 · Cited by 75
Moyo, B., Bloom, K. M., Scott, T. A., Ely, A., & Arbuthnot, P. B. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.003 · Cited by 70
Different Methods of Delivering CRISPR/Cas9 Into Cells
Chandrasekaran, A. P., Song, M., Kim, K.-S., & Ramakrishna, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.05.001 · Cited by 73
CRISPR-based genome editing in wheat: a comprehensive review and future prospects
Kumar, R., Kaur, A., Pandey, A., Mamrutha, H. M., & Singh, G. P. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04761-3 · Cited by 70
Sakuma, T., Masaki, K., Abe‐Chayama, H., Mochida, K., Yamamoto, T., & Chayama, K. (2016) · Genes to Cells · doi:10.1111/gtc.12437 · Cited by 72
Strategies for genetic manipulation of adult stem cell-derived organoids
Menche, C., & Farin, H. F. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00609-8 · Cited by 72
Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy
Ferrari, S., Valeri, E., Conti, A., Scala, S., Aprile, A., Micco, R. D., Kajaste‐Rudnitski, A., Montini, E., Ferrari, G., Aiuti, A., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.04.014 · Cited by 75
Critical roles of αII spectrin in brain development and epileptic encephalopathy
Wang, Y., Ji, T., Nelson, A. D., Glanowska, K. M., Murphy, G. G., Jenkins, P. M., & Parent, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95743 · Cited by 70
Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus
Liu, Y., Zhao, M., Gong, M., Xu, Y., Xie, C., Deng, H., Li, X., Wu, H., & Wang, Z. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.02.011 · Cited by 71
Aglawe, S. B., Barbadikar, K. M., Mangrauthia, S. K., & Madhav, M. S. (2018) · 3 Biotech · doi:10.1007/s13205-018-1355-3 · Cited by 70
Towards a new era in medicine: therapeutic genome editing
Porteus, M. H. (2015) · Genome Biology · doi:10.1186/s13059-015-0859-y · Cited by 69
CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma
Schokrpur, S., Hu, J., Moughon, D. L., Liu, P., Lin, L. C., Hermann, K. J., Mangul, S., Guan, W., Pellegrini, M. A., Xu, H., et al. (2016) · Scientific Reports · doi:10.1038/srep29032 · Cited by 70
USH2A Gene Editing Using the CRISPR System
Fuster‐García, C., García‐García, G., González-Romero, E., Jaijo, T., Sequedo, M. D., Ayuso, C., Vázquez‐Manrique, R. P., Millán, J. M., & Aller, E. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.003 · Cited by 70
Khosravi, M. A., Abbasalipour, M., Concordet, J., Berg, J. V., Zeinali, S., Arashkia, A., Azadmanesh, K., Buch, T., & Karimipoor, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.04.042 · Cited by 71
Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect
Deng, H., Huang, W., & Zhang, Z. (2019) · Nano Research · doi:10.1007/s12274-019-2465-x · Cited by 70
A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells
Waddington, S. N., Privolizzi, R., Karda, R., & O’Neill, H. C. (2016) · Current Stem Cell Reports · doi:10.1007/s40778-016-0037-5 · Cited by 69
High-Throughput Approaches to Pinpoint Function within the Noncoding Genome
Montalbano, A., Canver, M. C., & Sanjana, N. E. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.017 · Cited by 68
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 66
High-throughput functional evaluation of human cancer-associated mutations using base editors
Kim, Y., Lee, S., Cho, S., Park, J., Chae, D., Park, T., Minna, J. D., & Kim, S. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01276-4 · Cited by 66
Tools and targets: the dual role of plant viruses in CRISPR–Cas genome editing
Uranga, M., & Daròs, J. (2023) · The Plant Genome · doi:10.1002/tpg2.20220 · Cited by 68
Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector
Zhang, H., Bamidele, N., Liu, P., Ojelabi, O., Gao, X. D., Rodríguez, T., Cheng, H., Kelly, K. L., Watts, J. K., Xie, J., et al. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.0015 · Cited by 67
Hasanzadeh, A., Hamblin, M. R., Kiani, J., Noori, H., Hardie, J. M., Karimi, M., & Shafiee, H. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101665 · Cited by 73
CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy
Yao, S., He, Z., & Chen, C. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.067 · Cited by 70
Efficient genomic correction methods in human iPS cells using CRISPR–Cas9 system
Li, H. L., Gee, P., Ishida, K., & Hotta, A. (2016) · Methods · doi:10.1016/j.ymeth.2015.10.015 · Cited by 62
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
Murlidharan, G., Sakamoto, K., Rao, L., Corriher, T., Wang, D., Gao, G., Sullivan, P. M., & Asokan, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.49 · Cited by 69
Wang, L., Yang, Y., Breton, C. A., Bell, P. L., Li, M., Zhang, J., Che, Y., Saveliev, A., He, Z., White, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5701 · Cited by 67
Potent CRISPR-Cas9 inhibitors from Staphylococcus genomes
Watters, K. E., Shivram, H., Fellmann, C., Lew, R. J., McMahon, B., & Doudna, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917668117 · Cited by 70
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 68
Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections
Najafi, S., Tan, S. C., Aghamiri, S., Raee, P., Ebrahimi, Z., Jahromi, Z. K., Rahmati, Y., Nahand, J. S., Piroozmand, A., Jajarmi, V., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112743 · Cited by 69
DNase H Activity of Neisseria meningitidis Cas9
Zhang, Y., Rajan, R., Seifert, H. S., Mondragón, A., & Sontheimer, E. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.020 · Cited by 73
Liu, Z., Yang, N., Dong, J., Tian, W., Chang, L., Ma, J., Guo, J., Tan, J., Dong, A., He, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31168-9 · Cited by 67
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Alkhaleefah, F. K., Rahmani, A. H., & Khan, A. A. (2022) · 癌症：英文版 · doi:10.1002/cac2.12366 · Cited by 69
Li, Z., Wang, J., Xu, J.-P., Yang, X. F., & Yang, X. F. (2023) · Military Medical Research · doi:10.1186/s40779-023-00447-x · Cited by 72
Expression of CRISPR/Cas single guide RNAs using small tRNA promoters
Mefferd, A. L., Kornepati, A. V. R., Bogerd, H. P., Kennedy, E. M., & Cullen, B. R. (2015) · RNA · doi:10.1261/rna.051631.115 · Cited by 70
Yin, C., Zhang, T., Li, F., Yang, F., Putatunda, R., Young, W., Khalili, K., Hu, W., & Zhang, Y. (2016) · AIDS · doi:10.1097/qad.0000000000001079 · Cited by 67
One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids
Geurts, M. H., Gandhi, S., Boretto, M. G., Akkerman, N., Derks, L. L. M., van Son, G., Celotti, M., Harshuk-Shabso, S., Peci, F., Begthel, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40701-3 · Cited by 66
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gáll, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 73
Application of Genome Editing in Tomato Breeding: Mechanisms, Advances, and Prospects
Salava, H., Thula, S., Mohan, V., Kumar, R., & Maghuly, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020682 · Cited by 68
Evolving AAV-delivered therapeutics towards ultimate cures
He, X., Urip, B. A., Zhang, Z., Ngan, C. C., & Feng, B. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02034-2 · Cited by 70
The use of new CRISPR tools in cardiovascular research and medicine
Nishiga, M., Liu, C., Qi, L. S., & Wu, J. C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00669-3 · Cited by 71
Yoon, H. H., Ye, S., Lim, S., Jo, A., Lee, H., Hong, F., Lee, S. E., Oh, S., Kim, N., Kim, K., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0025 · Cited by 68
Enabling technology and core theory of synthetic biology
Zhang, X., Liu, C., Dai, J., Yuan, Y., Gao, C., Feng, Y. F., Wu, B., Wei, P., You, C., Wang, X., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2214-2 · Cited by 69
Raikwar, S. P., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1068-y · Cited by 67
CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 68
Lineage tracing using a Cas9-deaminase barcoding system targeting endogenous L1 elements
Hwang, B., Lee, W., Yum, S.-Y., Jeon, Y., Cho, N., Jang, G., & Bang, D. (2019) · Nature Communications · doi:10.1038/s41467-019-09203-z · Cited by 65
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Standard screening methods underreport AAV-mediated transduction and gene editing
Lang, J. F., Toulmin, S. A., Brida, K. L., Eisenlohr, L. C., & Davidson, B. L. (2019) · Nature Communications · doi:10.1038/s41467-019-11321-7 · Cited by 65
Genome editing in cardiovascular diseases
Mani, I. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.021 · Cited by 66
Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity
Tsuchida, C. A., Zhang, S., Doost, M. S., Zhao, Y., Wang, J., O’Brien, E., Fang, H., Li, C., Li, D., Hai, Z.-Y., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.002 · Cited by 62
Recent Advances in Improving Gene-Editing Specificity through CRISPR–Cas9 Nuclease Engineering
Huang, X., Yang, D., Zhang, J., Xu, J., & Chen, Y. E. (2022) · Cells · doi:10.3390/cells11142186 · Cited by 68
CRISPR Spherical Nucleic Acids
Huang, C., Han, Z., Evangelopoulos, M., & Mirkin, C. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07913 · Cited by 67
Strategies for precision modulation of gene expression by epigenome editing: an overview
Laufer, B. I., & Singh, S. M. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0023-7 · Cited by 70
de Solis, C. A., Ho, A., Holehonnur, R., & Ploski, J. E. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00070 · Cited by 65
Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review
Dangi, A. K., Sinha, R., Dwivedi, S., Gupta, S. K., & Shukla, P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00630 · Cited by 66
Creating cell and animal models of human disease by genome editing using CRISPR/Cas9
Zarei, A., Razban, V., Hosseini, S. E., & Tabei, K. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3082 · Cited by 68
Unified energetics analysis unravels SpCas9 cleavage activity for optimal gRNA design
Zhang, D., Hurst, T., Duan, D., & Chen, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820523116 · Cited by 63
Cas9 cleavage assay for pre-screening of sgRNAs using nicking triggered isothermal amplification
Zhang, K., Deng, R., Li, Y., Zhang, L., & Li, J. (2016) · Chemical Science · doi:10.1039/c6sc01355d · Cited by 64
Applying CRISPR–Cas9 tools to identify and characterize transcriptional enhancers
Lopes, R., Korkmaz, G., & Agami, R. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.79 · Cited by 65
Duan, Y., Tao, Y., Qu, Z., Chen, Y., Miranda, A., Zhou, X., Lok, K.-C., Chen, Y., Fu, A. K. Y., Gradinaru, V., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00759-0 · Cited by 64
CRISPR/Cas9 Technique for Temperature, Drought, and Salinity Stress Responses
Li, X., Xu, S., Aoyagi, M., Yuan, S., Iwama, T., Kobayashi, M., & Miura, K. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44060182 · Cited by 67
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 65
CRISPR/Cas9-gene editing approaches in plant breeding
Saini, H., Thakur, R., Gill, R., Tyagi, K., & Goswami, M. (2023) · GM crops & food · doi:10.1080/21645698.2023.2256930 · Cited by 76
NLRP3 inflammasome in health and disease (Review)
Wang, H., Ma, L., Su, W., Liu, Y., Xie, N., & Liu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5489 · Cited by 70
Designed nucleases for targeted genome editing
Lee, J., Chung, J., Kim, H. M., Kim, S., & Kim, S. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12465 · Cited by 70
Scott, T. A., Moyo, B., Nicholson, S., Maepa, M. B., Watashi, K., Ely, A., Weinberg, M. S., & Arbuthnot, P. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07642-6 · Cited by 66
RNA Polymerase II Activity of Type 3 Pol III Promoters
Gao, Z., Herrera-Carrillo, E., & Berkhout, B. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.05.001 · Cited by 65
Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy
Wang, L., Zheng, W., Liu, S., Li, B. J., & Jiang, X. (2018) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 66
DNA methylation and de-methylation using hybrid site-targeting proteins
Lei, Y., Huang, Y., & Goodell, M. A. (2018) · Genome biology · doi:10.1186/s13059-018-1566-2 · Cited by 67
Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing
Li, J., Hong, S., Chen, W., Zuo, E., & Yang, H. (2019) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2019.11.002 · Cited by 66
CRISPR/Cas9-Mediated Gene Correction to Understand ALS
Yun, Y., & Ha, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113801 · Cited by 66
Engineer chimeric Cas9 to expand PAM recognition based on evolutionary information
Ma, D., Xu, Z., Zhang, Z., Chen, X., Zeng, X., Zhang, Y., Deng, T., Ren, M., Sun, Z., Jiang, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08395-8 · Cited by 66
Prophages are associated with extensive CRISPR–Cas auto-immunity
Nóbrega, F. L., Walinga, H., Dutilh, B. E., & Brouns, S. J. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1071 · Cited by 63
Hu, Z., Zhang, C., Wang, S., Gao, S., Wei, J., Li, M., Hou, L., Mao, H., Wei, Y., Qi, T., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab148 · Cited by 67
Whole-genome sequencing reveals rare off-target mutations in CRISPR/Cas9-edited grapevine
Wang, X., Tu, M., Wang, Y., Yin, W., Zhang, Y., Wu, H., Gu, Y., Li, Z., Xi, Z., & Wang, X. (2021) · Horticulture Research · doi:10.1038/s41438-021-00549-4 · Cited by 67
Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment
Hodis, E., Triglia, E. T., Kwon, J., Biancalani, T., Zakka, L. R., Parkar, S., Hütter, J.-C., Buffoni, L., Delorey, T. M., Phillips, D., et al. (2022) · Science · doi:10.1126/science.abi8175 · Cited by 61
Evolution of CRISPR/Cas Systems for Precise Genome Editing
Hryhorowicz, M., Lipiński, D., & Zeyland, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814233 · Cited by 69
Zhao, C., Zheng, X., Qu, W., Li, G., Li, X., Miao, Y., Han, X., Liu, X., Li, Z., Ma, Y., et al. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21312 · Cited by 62
Deep mutational scanning of S. pyogenes Cas9 reveals important functional domains
Spencer, J. M., & Zhang, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-17081-y · Cited by 65
Genome editing technologies and their applications in crop improvement
Mishra, R., & Zhao, K. (2018) · Plant Biotechnology Reports · doi:10.1007/s11816-018-0472-0 · Cited by 72
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 65
Protein cages and virus-like particles: from fundamental insight to biomimetic therapeutics
Steinmetz, N. F., Lim, S., & Sainsbury, F. (2020) · Biomaterials Science · doi:10.1039/d0bm00159g · Cited by 62
Gene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 64
ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected
Boutin, J., Cappellen, D., Rosier, J., Amintas, S., Dabernat, S., Bedel, A., & Moreau‐Gaudry, F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0120 · Cited by 59
Application of CRISPR/Cas9 for biomedical discoveries
Riordan, S. M., Heruth, D. P., Zhang, L. Q., & Ye, S. Q. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0027-9 · Cited by 66
Chen, F., Rosiene, J. A., Che, A., Becker, A. J., & LoTurco, J. J. (2015) · Development · doi:10.1242/dev.118836 · Cited by 62
Genome Editing with CRISPR-Cas9: Can It Get Any Better?
Haeussler, M., & Concordet, J. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.04.008 · Cited by 65
Barakate, A., & Stephens, J. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00765 · Cited by 64
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
